Relationship between idiopathic hypereosinophilic syndrome, eosinophilic leukemia, and systemic mastocytosis
- 11 August 2004
- journal article
- review article
- Published by Wiley in American Journal of Hematology
- Vol. 77 (1) , 82-85
- https://doi.org/10.1002/ajh.20088
Abstract
Chronic eosinophilic leukemia is a neoplastic condition with persistent eosinophilia as the major hematological abnormality and with the eosinophils being part of the neoplastic clone. Some cases can be recognized by traditional hematological criteria, but many can be recognized only when a clonal cytogenetic or molecular genetic abnormality is demonstrated. A range of cytogenetic and molecular genetic abnormalities has been recognized, including both those seen in other myeloid malignancies (such as trisomy 8, monosomy 7, and 20q−) and those that are particularly linked to eosinophil differentiation (such as rearrangements of PDGFRB, FGFR1, and PDGFRA, the latter with formation of a FIP1L1–PDGFRA fusion gene). The discovery of the FIP1L1–PDGFRA fusion gene has led to the recognition that many patients who would previously have been regarded as having idiopathic hypereosinophilia actually have chronic eosinophilic leukemia. The same fusion gene has also been found in patients with hypereosinophilia and atypical bone marrow mast cells but whether this syndrome should be regarded as a variant of eosinophilic leukemia or as a variant of systemic mastocytosis remains to be established. Am. J. Hematol. 77:82–85, 2004.Keywords
This publication has 14 references indexed in Scilit:
- 17-Allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cellsBlood, 2004
- Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndromeBlood, 2004
- CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapyBlood, 2003
- Hypereosinophilic syndrome with elevated serum tryptase versus systemic mast cell disease associated with eosinophilia: 2 distinct entities?Blood, 2003
- Imatinib for systemic mast-cell diseaseThe Lancet, 2003
- Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsivenessBlood, 2003
- Antithrombin Phe229Leu: a new homozygous variant leading to spontaneous antithrombin polymerization in vivo associated with severe childhood thrombosisBlood, 2003
- A Tyrosine Kinase Created by Fusion of thePDGFRAandFIP1L1Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic SyndromeNew England Journal of Medicine, 2003
- Abnormal Clones of T Cells Producing Interleukin-5 in Idiopathic EosinophiliaNew England Journal of Medicine, 1999
- THE HYPEREOSINOPHILIC SYNDROMEMedicine, 1975